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Abstract
Study objective: The acute management of patients on warfarin with spontaneous or traumatic intracranial
hemorrhage continues to be debated in the medical literature. The objective of this paper was to conduct a
structured review of the medical literature and summarize the advantages and risks of the available treatment
options for reversing warfarin anticoagulation in patients who present to the emergency department with acute
intracranial hemorrhage.
Methods: A structured literature search and review of articles relevant to intracranial hemorrhage and warfarin and
treatment in the emergency department was performed. Databases for PubMed, CINAHL, and Cochrane EBM Reviews
were electronically searched using keywords covering the concepts of anticoagulation drugs, intracranial hemorrhage
(ICH), and treatment. The results generated by the search were limited to English- language articles and reviewed for
relevance to our topic. The multiple database searches revealed 586 papers for review for possible inclusion. The final
consensus of our comprehensive search strategy was a total of 23 original studies for inclusion in our review.
Results: Warfarin not only increases the risk of but also the severity of ICH by causing hematoma expansion.
Prothrombin complex concentrate is statistically significantly faster at correcting the INR compared to fresh frozen
plasma transfusions. Recombinant factor VIIa appears to rapidly reverse warfarin’s effect on INR; however, this
treatment is not FDA-approved and is associated with a 5% thromboembolic event rate. Slow intravenous dosing
of vitamin K is recommended in patients with ICH. The 30-day risk for ischemic stroke after discontinuation of
warfarin therapy was 3-5%. The risks of not reversing the anticoagulation in ICH generally outweigh the risk of
thrombosis in the acute setting.
Conclusions: Increasing numbers of patients are on anticoagulation including warfarin. There is no uniform
standard for reversing warfarin in intracranial hemorrhage. Intravenous vitamin K in addition to fresh frozen plasma
or prothrombin complex concentrate is recommended be used to reverse warfarin-associated intracranial
hemorrhage. No mortality benefit for one treatment regimen over another has been shown. Emergency physicians
should know their hospital’s available warfarin reversal options and be comfortable administering these treatments
to critically ill patients.
Introduction
Outpatient prescriptions for warfarin increased 45% to 31
million in the United States during the period of 1998-
2004 [1]. Warfarin usage will increase with the rising pre-
valence of diseases such as atrial fibrillation and the aging
of the population [2]. There are more than 1 million
emergency department (ED) visits annually for traumatic
b r a i ni n j u r y( T B I )i nt h eU S[ 3 ] .T h eu s eo fw a r f a r i n
increases a patient’s risk for spontaneous intracranial
hemorrhage and overall mortality. The incidence of
spontaneous intracranial hemorrhage (ICH) is 7-10 times
higher among patients taking warfarin compared to those
not on anticoagulation [4]. Patients taking warfarin ther-
apy account for 8-14% of all ICH [4,5], and ICH occurs
8-10 times more frequently in individuals on warfarin
[4,6]. The annual risk of ICH in patients treated with
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[7-10]. ICH is the most lethal form of CVA with 30-day
mortality rates estimated at 30-55% [8,9,11], while those
on warfarin have a higher risk of death at 30 days of 43-
60% [9,11,12]. Alarmingly, between 50-90% of all ICH
occurs while the INR is within the target range [7].
Different therapies such as fresh frozen plasma (FFP),
vitamin K, prothrombin complex concentrates (PCC),
which contain factors II, VII, IX, and X, and recombi-
nant activated factor VII (rfVIIa) have all been used as
ways to treat ICH in this high-risk population, either
alone or in combination. Acute interventions that mini-
mize or arrest ongoing bleeding and hematoma size are
likely to be critical for improving outcomes [4,13]. This
makes the role of the ED physician paramount in diag-
nosis and management of warfarin-associated ICH in a
timely manner.
The objective of this systematic review is to summar-
ize the medical literature regarding the benefits and
risks of the available treatment options to reverse war-
farin anticoagulation in patients with acute ICH.
Materials and methods
Study design and data sources
We conducted a comprehensive literature search of the
databases MEDLINE
® (via PubMed
®; 1950-) through
2009 using a combination of Medical Subject Terms
(MESH
®) and keywords covering the concepts of anticoa-
gulation drugs, intracranial hemorrhage (ICH), and treat-
ment. A sample search strategy was “(Anticoagulants[mh]
OR Anticoagulants [Pharmacological Action]) AND Intra-
cranial Hemorrhages[mh] AND therapeutics[mh] AND
English[la],” which yielded 1,082 citations as of 29 Decem-
ber 2009. We limited the search to study designs that
included the following: clinical trial, meta-analysis, and
practice guideline, randomized controlled trial. This search
resulted in a total of 382 (/29 December 2009) abstracts.
Two independent reviewers (BFB, TCN) examined the
abstracts and made separate recommendations for inclu-
sion. A third reviewer (TWB) adjudicated any disagree-
ments between the two primary reviewers. This review
yielded 37 articles that were selected for full-text evalua-
tion based on the following inclusion/exclusion criteria:
1. Patient taking an anticoagulant drug, with prefer-
ence for warfarin
2. Patient diagnosed with intracranial hemorrhage
3. Article contains information on treatment/man-
agement of ICH
4. Article contains raw data and was original
research study
From these, 14 additional articles were hand selected
from the papers’ references for inclusion. This yielded a
t o t a lo f5 1s t u d i e s ,o fw h i c h3 0w e r er e v i e w s .T h e
reviews were excluded, resulting in 21 original studies
for evaluation.
We additionally searched the Cochrane Database of
Systematic Reviews (via OVID
®)a n dt h eC u m u l a t i v e
Index of Nursing and Allied Health Literature
(CINAHL
® Via EBSCOhost
®) for relevant reviews and
articles as of December 2009. We identified no relevant
reviews in the Cochrane Database. A search of
CINAHL–using ((MH “Intracranial Hemorrhage+”)o r
(MH “Cerebral Hemorrhage+”)) AND ((MH “Anticoagu-
lants+”)o r( M H“Heparin+”)o r( M H“Warfarin”))–lim-
ited to English language, Clinical Trials, Journal Articles,
Practice Guidelines, Research, and Systematic Reviews,
retrieved 204 abstracts of which 31 were selected. Three
of the 31 were eliminated as duplicates to the PubMed
search, yielding 28 that were added to the PubMed
results for further examination. Two independent
reviewers (BFB, TWB) examined the 28 abstracts and
chose two for ultimate inclusion in the paper based on
the above inclusion/exclusion criteria. The final consen-
sus of our comprehensive search strategy was a total of
23 original studies for inclusion in our review. Two
reviewers assessed the quality of evidence for each of
these 23 manuscripts using the GRADE system that
classifies studies from high to very low based on study
design and internal validity measures [14].
Results
The available literature consists primarily of small case
series and retrospective cohort studies with the majority
classified as low, thus limiting the strength of findings
[14]. Variation in federalr e g u l a t o r yd r u ga g e n c y
approvals also impacts reporting as PCC is approved
and considered a standard reversal treatment in most
nations [6]. The US Federal Drug Agency, however, has
yet to approve a PCC formulation that is sufficient for
warfarin reversal, thus leaving thawed plasma as the
only available clotting factor option for rapid reversal.
This review focuses on warfarin-associated intracranial
hemorrhage (WAICH) from spontaneous causes; how-
ever, the acute management of WAICH appears to
include the same treatments regardless of whether the
ICH was spontaneous or traumatic. However, the litera-
ture on traumatic WAICH is limited because of small
sample sizes (Table 1) [15-18].
Rationale for rapid correction of anticoagulation in the
emergency department
Warfarin not only increases the risk of but also the
severity of ICH by causing hematoma expansion [10].
Hematoma progression was found to occur in nearly
40% of ICH patients with ICH in the first few hours fol-
lowing symptom onset [4]. Hematoma enlargement
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with ICH [19]. As volume and ventricular extension
increase, earlier patient deterioration is observed [20].
Goldstein et al. found that for every 30-min delay in
FFP administration, the probability of successful INR
reversal within 24 h decreases by 20% [21]. Interventions
aimed at preventing this growth are paramount as larger
hematomas are associated with poorer functional out-
comes [13,20].
Administration of prothrombin complex concentrates
versus fresh frozen plasma
Warfarin inhibits the production of vitamin K-depen-
dent clotting factors; therefore, patients with WAICH
should have their clotting factors repleted. Treatment
options for the repletion of clotting factors include FFP
and PCC.
FFP contains all coagulation factors in non-concen-
trated form. FFP is more universally available at hospi-
tals, especially in the US, compared to PCC.
Administration of FFP, a blood product, requires com-
patibility testing and carries the risk of blood borne
infection transmission and transfusion-related acute
lung injury (TRALI). FFP is stored frozen, thus requiring
at least 15-20 min to thaw [6]. Large FFP volumes (800
to 3,500 mL) are often needed to treat serious hemor-
rhages [22]. This large volume may result in acute
decompensated heart failure in patients with atrial fibril-
lation or cardiac valve disease and ventricular dysfunc-
tion. Less common adverse events including allergic
reactions are also possible with FFP [6].
PCC contains coagulation factors II, VII, IX, and X, and
proteins C, S, and Z in concentrated form [6]. European
and Australian practice protocols recommend the use of
PCC in bleeding emergencies [6]. PCC is not widely
available in US hospitals, and, while cheaper than rfVIIa,
it is more expensive than FFP. PCC risks include poten-
tial thrombotic complications and disseminated intravas-
cular coagulation (DIC) [6]. The optimal PCC dosing is
calculated according to patient age, body weight, severity
of INR prolongation, and desired level of INR correction
with typical dosages of 25 to 50 IU/kg [19].
Studies have compared the use of PCC and FFP in
patients with WAICH, measuring which treatment cor-
rected the INR faster (Table 2). Makris et al. found that
PCC outperformed FFP at repleting factors II, VII, IX, and
X [23]. PCC administration normalized the INR, whereas
the INR remained elevated in patients given FFP [23]. Fre-
driksson et al. retrospectively found that PCC worked sig-
nificantly faster than FFP. The mean INR decreased from
2.83 to 1.22 within 4.8 h in the ten patients treated with
PCC compared with an INR decrease from 2.97 to 1.74
within 7.3 h in those seven patients receiving FFP [24].
These findings, however, are not surprising as FFP lacks
concentrated factors and has an INR of 1.3-1.4.
Cartmill et al. prospectively studied 12 patients with
WAICH. They treated six patients with 50 μg/kg intrave-
nous (IV) PCC and 10 mg IV vitamin K. Six matched
patients were treated with 4 units of FFP and 10 mg IV
vitamin K. The investigators measured the INR at base-
line and 15 min after treatment. The PCC group had sig-
nificantly faster and complete reversal compared to the
Table 1 Studies investigating reversal of warfarin anticoagulation in traumatic intracranial hemorrhage
Author Study type Patient population Intervention Result Grade
[14]
Bartal et al.
2007
Prospective 7 patients on warfarin
with traumatic ICH
All received vitamin K and 6-12 units of
FFP. INR was still > 1.3 in all, so 40-90
μg/kg rfVIIa was given. INR dropped
below 1.3, and all underwent
neurosurgery
rfVIIa lowered the INR into operable
range in all patients.
Low
Baldi et al.
2006
Prospective 232 on warfarin or
acenocumarol or with INR
equal or > 2 with
spontaneous or traumatic
ICH
FFP used in 22% of patients, vitamin K in
41%, PCC in 6% and factor VII
concentrate in 3%. Many did not receive
any reversal treatment
No statistical differences were found in
the outcomes of patients with or
without medical therapy
Low
Kalina et
al. 2008
Prospective 46 trauma patients on
warfarin with ICH with
INR > 1.5
Institution developed protocol for
trauma patients with ICH taking warfarin
with INR > 1.5. Patients given weight-
based dose of PCC (concentrated II, VII,
IX, X). All given 5 mg vitamin K as well.
Patients could receive FFP as well in
protocol group
Protocol resulted in increased number of
patients receiving PCC. Protocol patients
had improved times to INR
normalization, patients having reversal of
coagulopathy, and shorter times to
surgery. No difference in ICU days,
hospital days, or mortality. 2/48 that got
PCC had DVT
Low
Ivascu et
al. 2006
Retrospective 57 patients with
traumatic WAICH from fall
or MVC
Established and implemented protocol
to treat traumatic WAICH. All 35 protocol
patients received FFP. Only 14/22
patients in the pre-protocol group
received FFP
Mortality and reversal times of INR were
similar between the protocol instituted
group and the pre-protocol group
Low
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and FFP groups were 1.32 and 2.3, respectively [25].
Boulis et al. performed a randomized control trial
comparing treatment with FFP and FFP + factor IX
complex concentrate (FIXCC) in patients with acute
ICH. FIXCC, similar to other PCC formulations, con-
tains high concentrations of activated vitamin K-depen-
dent factors (factors II, VII, IX, and X). The study
included 13 patients, 8 receiving FFP alone and 5 receiv-
ing FFP and FIXCC. All patients received vitamin K 10
mg subcutaneously (SQ). They reported significant dif-
ferences in time to correction, rate of correction, and
volume of FFP required for correction between the FFP
group (mean 8.9 h, 2,700 cc) and the FIXCC + FFP
group (mean 2.95 h, 399 cc) [22]. Another study retro-
spectively evaluated ten patients treated with FIXCC +
FFP + vitamin K and nine patients treated with FFP +
vitamin K alone [26]. FIXCC used along with FFP and
vitamin K trends toward faster normalization of INR
than with FFP and vitamin K alone.
In conclusion, PCC is statistically significantly faster
than FFP at correcting the INR in patients taking war-
farin. None of these studies, however, demonstrated a
statistically significant clinical outcome difference
between those treated with FFP or PCC.
Use of recombinant factor VIIa for warfarin reversal in
ICH (Table 3)
Recombinant factor VIIa (rfVIIa) is the cloned activated
form of endogenous human hemostatic factor VII. Its
original use was for hemophiliac patients. rfVIIa is given
as an IV bolus over 2-5 min, with its onset of action
being almost immediate and clinically apparent hemos-
tasis observed within 10 min [27]. However, it is expen-
sive to use, with a 1.2-mg vial costing approximately
USD$1,369 [27]. There is no risk of blood-borne patho-
gen transmission, but there is a clinically important risk
of thrombotic complications. A systematic review of 35
randomized clinical trials reported arterial and venous
thromboembolic rates of 5.5% and 5.3%, respectively
[28]. The half-life of rfVIIa is short unless the dose is
increased to 120 μg / k g .A tt h i sd o s e ,r f V I I aw a sa b l et o
correct INR for periods of 24 h without signs of sys-
temic coagulation in one study [27].
Bartal et al. in 2007 did a prospective study on seven
patients with WAICH. They all received vitamin K and
between 6- 12 units of FFP. The INR was still greater
than 1.3 in all, and so 40-90 μg/kg IV rfVIIa was given.
This rapidly corrected the INR to below 1.3 [15]. Soren-
sen et al. evaluated six patients who all received vitamin
K, and three were transfused FFP. The patients’ INRs
remained elevated (> 1.5), so each patient was given 10-
40 μg/kg rfVIIa in preparation for emergent neurosur-
gery. All six patients’ INRs were ≤ 1 . 5w i t h i n1 0m i no f
rfVIIa administration and underwent neurosurgery [29].
Freeman et al. treated seven patients with 15-90 μg/kg
of rfVIIa. All patients but one also received vitamin K
and FFP. They found that an rfVIIa IV bolus rapidly
lowered the INR to normalized levels [30]. Brody treated
15 patients with vitamin K 10 mg IV or SQ and FFP.
Table 2 Studies investigating PCC versus FFP for anticoagulation reversal in warfarin-associated intracranial
hemorrhage
Author Study type Patient
population
Intervention Result Grade
[14]
Makris et al.
1997
Prospective 16 patients with
WAICH, along
with 12 “similar
subjects”
Vitamin K 1-5 mg IV given to all patients.
16 patients got PCC and 12 FFP
PCC repleted factors II, VII, IX, and X better
than FFP. In patients given FFP, INR
remained elevated. 28/29 patients given
PCC had INR correction
Moderate
Fredriksson
et al. 1992
Retrospective 17 patients with
WAICH
All patients received vitamin K 10-20 mg IV.
Of the 17 total patients, 10 received PCC
and 7 received FFP
PCC significantly decreased the INR from
2.83 to 1.22 within 4.8 h, compared with a
decrease in INR from 2.97 to 1.74 within
7.3 h in the FFP group. Signs and
symptoms of ICH progressed more in
those treated with FFP than with PCC
Low
Boulis et al.
1999
Prospective,
randomized
controlled
trial
13 patients with
WAICH
All patients received vitamin K 10 mg
subcutaneously. 8 patients received FFP. 5
patients received weight-based dosing of
factor IX complex concentrate (FIXCC) in
addition to FFP
Significant differences were found in time
to correction, rate of correction, and
volume of FFP required for correction
between the FFP group (8.9, 2,700 mL) and
the FIXCC + FFP group (2.95, 399 mL)
Moderate
Cartmill et al.
2000
Prospective 12 patients with
spontaneous
WAICH
6 patients treated with 50 μg/kg IV PCC
along with vitamin K 10 mg IV. 6 matched
patients treated with 4 units of FFP and
vitamin K 10 mg IV. INR re-checked 15 min
after treatment
PCC group had significantly faster and
complete reversal compared to the FFP
group. Mean post-treatment INRs were
1.32 in PCC group and 2.3 in FFP group
Low
Siddiq et al.
2008
Retrospective 19 patients with
diagnosis of
WAICH
10 patients treated with PCC, vitamin K,
and FFP, and 9 patients treated with FFP
and vitamin K
PCC along with FFP and vitamin K trends
toward faster normalization of INR than
with FFP and vitamin K alone
Low
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well. Median time from presentation to INR < 1.3 was
significantly lower (p = 0.016) in the rfVIIa group (8.8
h) compared with the FFP group (32 h). One patient
with ESRD developed DIC after three doses of rfVIIa.
One patient in the FFP group developed pulmonary
edema [31].
Nishijima et al. retrospectively analyzed 40 patients
with WAICH including 20 who received rfVIIa. They
found no difference in mortality. Seven patients died in
each group. Four of the 20 thrombotic complications
occurred in the rfVIIa group and in the control group
(p > 0.05). Time to normalization of INR was signifi-
cantly faster (p < 0.001) in the rfVIIa cohort (mean =
4.8 h) versus the standard cohort (mean = 17.5 h) [32].
In conclusion, recombinant factor VIIa appears to
rapidly reverse warfarin’se f f e c t so nI N R .T h i si sn o ta n
FDA-approved use. This potential rapid reversal benefit
must be weighed against the reported 5% risk of a
thromboembolic event.
Is vitamin K safe and effective and how should it be
given?
Vitamin K is a necessary component within the liver in
order to help carboxylate factors II, VII, IX, and X to
their active forms. When warfarin is given, it blocks the
reductase that converts oxidized vitamin K back to vita-
min K for reuse [4]. A vitamin K shortage within the
liver creates a coagulation cascade deficit. Vitamin K
replacement in patients on warfarin can be administered
by oral, SQ, or IV route. Oral and SQ routes have vari-
able times to onset and slower absorption rates. Intrave-
nous dosing is recommended in those patients with
ICH. Dosages of 10 mg given by slow IV infusion over
30 min has been recommended [11]. The time to onset
is at least 2-6 h and often more than 24 h are needed to
achieve effective response [4]. Other factor replacement
must be given in the interim as well. The incidence of
anaphylactic reaction to IV vitamin K is exceedingly
rare with a reported rate of 3 out of 10,000 doses [4].
Many of the reported anaphylaxis episodes occurred
with older vitamin K formulations containing poly-
ethoxylated castor oil, while the modern micelle formu-
lation is thought to have a lower risk of anaphylactoid
reactivity [33]. A 2001 review of anaphylactoid reactions
associated with vitamin K reported 23 (3 fatal) case
reports and 132 FDA-reported adverse drug events from
IV vitamin K, 32 individuals following intramuscular
administration, 13 patients following SQ vitamin K, and
7 individuals following oral vitamin K [34]. In conclu-
sion, 5-10 mg of vitamin K should be given slowly by IV
when a patient presents with WAICH.
What is the risk of thrombosis after warfarin reversal?
Patients who take warfarin for atrial fibrillation, pulmon-
ary embolus, deep vein thrombosis, or mechanical heart
valves are at risk for thrombotic or embolic risk when
their anticoagulation is reversed. Physicians need to
Table 3 Studies investigating recombinant factor VIIa for anticoagulation reversal in intracranial hemorrhage
Author Study type Patient
population
Intervention Result Grade
[14]
Bartal et al.
2007
Prospective 7 patients on
warfarin with
traumatic ICH
All received vitamin K and between 6- 12
units of FFP. INR was still > 1.3 in all and so
40-90 μg/kg rfVIIa was given. INR went
below 1.3, and all underwent neurosurgery
The use of rfVIIa lowered the INR into
operable range in all patients
Low
Sorensen et al.
2003
Retrospective 6 patients with
WAICH
All received vitamin K, three received FFP.
INR still > 1.5 so 10-40 μg/kg rfVIIa given to
each patient. All underwent NSGY
All INRs were equal to or < 1.5 within 10
min of rfVIIa being given and allowed for
safe neurosurgical procedure
Very
low
Freeman et al.
2004
Retrospective 7 patients with
symptomatic
non-traumatic
WAICH
Treated with 15-90 μg/kg of rfVIIa. Vitamin
K given to all patients as well except for
one who died prior. All patients but one
also received FFP. Two underwent
neurosurgical procedures
IV bolus rfVIIa rapidly lowered the INR to
normalized levels
Very
low
Brody et al.
2005
Retrospective 28 patients with
WAICH with INR
> 1.3
15 patients received 10 mg IV or
subcutaneously vitamin K and FFP. 12
patients received vitamin K, FFP, and rfVIIa
as well
Median time from presentation to INR < 1.3
was 8.8 h in the rfVIIa group and 32 h in
the FFP group. Significantly lower. One
patient with ESRD developed DIC after
three doses of rfVIIa. One patient in the FFP
group developed pulmonary edema
Low
Nishijima et al.
2010
Retrospective 40 patients with
traumatic
WAICH and INR
1.3 or greater
20 patients received rfVIIa and 20 did not.
In both groups some patients received
pRBCs, FFP, and vitamin K. Patient
characteristics were similar in both groups
No difference in mortality. 7 patients died
in each group. There were 4/20 thrombotic
complications in the rfVIIa group and 1/20
in the control. This was not statistically
significant. Time to INR normalization was
faster in the rfVIIa cohort mean = 4.8 h
than in the standard cohort mean = 17.5 h
Low
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gulation. Most reviews and studies view it as an accepta-
ble risk for reversal in the setting of warfarin ICH [7].
Phan et al. showed that discontinuation of warfarin ther-
apy for 1 to 2 weeks in patients with a high embolic risk
is relatively safe [35]. The risk for ischemic stroke after
discontinuation of warfarin therapy within 30 days was
3% for metallic valves, 3% with atrial fibrillation, and 5%
in those with recurrent TIA or minor stroke [35]. Once
warfarin is restarted, early recurrence of ICH is exceed-
ingly uncommon [35]. In conclusion, treating physicians
should correct the INR no matter the reason the patient
is on anticoagulation. The risk of not treating the ICH
and lowering the INR generally outweighs the risk of
thrombosis in the acute setting.
Does rapid correction of anticoagulation improve patient
mortality?
Numerous small studies (Table 4) have reported that the
warfarin reversal agents result in more rapid INR nor-
malization and decreased intracranial hematoma expan-
sion [36-40]. The medical literature’s reporting of these
reversal agents’ impact on patient survival is limited to
relatively small, primarily retrospective, studies that have
investigated whether treatment with a single agent, com-
bination therapy of FFP, vitamin K, PCC, or no reversal
therapy affects patient mortality (Table 5) [41-43]. Ber-
waerts et al. studied 68 patients with WAICH and 126
not on warfarin with ICH between 1993-1999 [41]. The
treatment of the 68 patients on warfarin consisted of
the following: 19 received only vitamin K, 11 vitamin K
and FFP, 5 FFP alone, 3 vitamin K and FFP and factor
IX, 2 vitamin K and factor IX, 2 factor IX alone, and 26
received no therapy and were treated with an “expectant
attitude.” Overall the patients in the study who were not
on warfarin had an inpatient mortality of 18% versus
38% of those on warfarin [41]. The authors reported no
difference in mortality among patients with WAICH
who had been reversed with any combination or had
not been reversed at all. This method of retrospectively
assessing treatment effect is confounded by a great
number of treatment arms and small number of
patients.
Sjoblom et al. performed a similar study in 2001, ret-
rospectively reviewing charts of 136 patients with
WAICH between 1993-1996, who all received some
form of reversal [20]. Either single therapy or combina-
tions of vitamin K, factor IX, FFP, or no therapy was
administered. There was no evidence that any treatment
strategy was superior to the other [20]. Huttner et al.
looked at 55 patients with WAICH and compared vita-
min K, PCC, and FFP alone or in some combination.
They found the incidence and extent of hematoma
growth were significantly lower in the PCC-treated
group [42]. If the INR was normalized within 2 h, then
the influences of FFP and PCC on hematoma growth
were similar [42].
In conclusion, multiple small retrospective studies
with many treatment arms did not find any difference in
one treatment over another or no treatment at all in
correcting the INR of those patients with WAICH
[20,21,41,42]. However, these may very well reflect a
type II error given their underpowered sample sizes. A
large well-designed prospective study is still needed to
determine whether rapid correction of anticoagulation is
effective at improving patient-oriented outcomes (i.e.,
Table 4 Studies investigating multiple treatment options for anticoagulation reversal in warfarin-associated
intracranial hemorrhage
Author Study type Patient population Intervention Result Grade
[14]
Rabinstein
and Wijdicks
2007
Retrospective 13 patients with
spontaneous WAICH
Vitamin K and FFP in “doses
deemed appropriate for each case.”
Neurosurgical intervention once
INR < 1.4
Median time to reversal 6.5 h (INR < 1.4).
Recovery in 65% of those patients who fully
awoke within 36 h after evacuation
Low
Yasaka et al.
2005
Prospective 35 patients with
WAICH
Varying doses of PCC (200- 1,500
IU) were given to see what the
optimal dose was for INR
correction
200 IU did not decrease 50% of the patients
below 2.0 INR. 500 IU decreased the INR to <
1.5 in 96% of patients with initial INR < 5.0. All
patients treated with 1,000 IU-1,500 IU had INR
decrease to < 1.3
Low
Preston 2002 Prospective 10 patients with
WAICH
PCC dose range 25-50 μg/kg was
used in each patient as reversal as
well as vitamin K 2-5 mg IV
Median INR was 3.98 prior to treatment and 20
min after treatment < 1.9 with almost all < 1.3
Low
Nitu et al.
1998
Retrospective 1 patient with WAICH;
17 patients on
warfarin with other
bleeding
Factor IX and factor VII concentrate
given to patients
INR in the patient with ICH went from 5.9 to
post-treatment 1.8 within 15 min
Low
Lee et al.
2006
Retrospective 45 patients with
WAICH
Varying doses of FFP and vitamin K
were given for reversal
The median time for door to INR normalization
was 30 h (14 to 49.5), with 4 patients’
hematomas enlarging after INR normalization
Low
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zation of healthcare resources.
Conclusions
Emergency medicine physicians will see increasing num-
bers of patients on warfarin as the population ages. Phy-
sicians must know how to treat patients who present
with warfarin-associated intracranial hemorrhage. PCC
appears to normalize the INR faster than FFP. Vitamin
K is generally safe and should be administered by slow
IV infusion in all patients who present with WAICH.
rfVIIa has not yet been approved for use in WAICH,
but has shown promising results in fast normalization of
INR in a small subset of patients, but at the cost of a
5% thromboembolic event rate. Despite the multiple
treatment options to correct anticoagulation, studies
have yet to demonstrate improved patient survival with
any particular treatment strategy.
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Table 5 Studies investigating the available anticoagulation reversal agents’ impact on patient survival
Author Study type Patient
population
Intervention Result Grade
[14]
Berwaerts et al.
2000
Retrospective 68 patients with
WAICH
19 patients received vitamin K only, 11
vitamin K + FFP, 5 FFP, 3 vitamin K + FFP
+ factor IX, 2 vitamin K + factor IX, 2
factor IX, and 26 were treated with an
“expectant attitude”
No significant difference in mortality rate
among patients who had been reversed
with any combination of reversal agents
or had not been reversed
Low
Sjoblom et al.
2001
Retrospective 136 patients with
WAICH who
received some
form of reversal
Either single therapy or combinations of
vitamin K, factor IX, FFP, or no therapy
was administered
No evidence that any treatment strategy
was superior to the others
Moderate
Huttner et al.
2006
Retrospective 55 patients with
WAICH
Compared vitamin K, PCC, and FFP alone
or in some combination
Incidence and extent of hematoma
growth were significantly lower in the
PCC-treated group. If the INR was
normalized within 2 h then FFP and PCC
influence on hematoma growth were
similar
Low
Goldstein et al.
2006
Retrospective 69 patients with
non traumatic
WAICH with INR
> 1.4
Patients received no therapy, FFP, vitamin
K, or combination
Patients whose INR was successfully
reversed within 24 h had a shorter time
from diagnosis to first dose of FFP (90 vs.
210 min). Shorter time to vitamin K as
well predicted INR correction. Every 30
min of delay in the first dose of FFP was
associated with 20% decreased odds of
INR reversal within 24 h. No ED
intervention was associated with
improved clinical outcome
Moderate
Yasaka et al.
2003
Prospective 15 patients with
WAICH
9 PCCs with vitamin K 10-20 mg IV, 2
PCCs alone or 4 with vitamin K 10-20 mg
IV alone were administered based on
decision of treating MD
Vitamin K lowered the INR after 12-24 h
to normalized range. PCC with or
without vitamin K was more effective at
rapidly correcting the increased INR. PCC
without vitamin K administration led to a
recurrent increase in INR after 12-24 h
Low
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